The rationale for combining GLP-1 and glucagon is therefore to utilize the anti-obesity properties of glucagon with the appetite-regulating and anti-diabetic properties of GLP-1. This evidence concerns the gene GCG and obesity due to melanocortin 4 receptor deficiency.